Global Pharmaceutical Cdmo Market Size & Outlook
Global pharmaceutical cdmo market, 2021-2033 (US$M)
Related Markets
Global pharmaceutical cdmo market highlights
- The global pharmaceutical cdmo market generated a revenue of USD 155,508.3 million in 2024 and is expected to reach USD 293,555.0 million by 2033.
- The market is expected to grow at a CAGR (2025 - 2033) of 7.3% by 2033.
- In terms of segment, api accounted for a revenue of USD 126,490.6 million in 2024.
- API is the most lucrative product segment registering the fastest growth during the forecast period.
- In terms of region, Asia Pacific was the largest revenue generating market in 2024.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2033.
Global data book summary
| Market revenue in 2024 | USD 155,508.3 million |
| Market revenue in 2033 | USD 293,555.0 million |
| Growth rate | 7.3% (CAGR from 2025 to 2033) |
| Largest segment | Api |
| Fastest growing segment | API |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | API, Drug Product |
Other key industry trends
- In terms of revenue, the North America accounted for 28.0% of the global pharmaceutical cdmo market in 2024.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2033.
- By country, China is the fastest growing regional market and is projected to reach USD 39,514.1 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pharmaceutical CDMO Market Scope
Pharmaceutical CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Seqens | View profile | 1001-5000 | Écully, Rhone-Alpes, France, Europe | https://www.seqens.com/en |
| Bushu Pharmaceuticals | View profile | - | Saitama, Saitama, Japan, Asia | http://bushu-seiyaku.co.jp/en/ |
| Recipharm Venture Fund | View profile | - | Stockholm, Stockholms Lan, Sweden, Europe | - |
| Cambrex | View profile | 1001-5000 | East Rutherford, New Jersey, United States, North America | http://www.cambrex.com |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | http://cordenpharma.com |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | http://www.piramalpharmasolutions.com/ |
| Siegfried Holding AG | View profile | 4180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | https://www.siegfried.ch |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| Wuxi AppTec Co Ltd | View profile | 41116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | https://www.wuxiapptec.com |
| Nipro Corp | View profile | 39713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | http://www.nipro.co.jp |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Global pharmaceutical cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical cdmo market will help companies and investors design strategic landscapes.
Api was the largest segment with a revenue share of 81.34% in 2024. Horizon Databook has segmented the Global pharmaceutical cdmo market based on api, drug product covering the revenue growth of each sub-segment from 2021 to 2033.
- Global Pharmaceutical CDMO Product Outlook (Revenue, USD Million, 2021-2033)
- API
- Synthetic
- Solid
- Liquid
- Biotech
- Synthetic
- Drug Product
- Oral Solid Dose
- Semi-solid Dose
- Liquid Dose
- Others
- API
- Global Pharmaceutical CDMO Work Flow Outlook (Revenue, USD Million, 2021-2033)
- Clinical
- Commercial
- Global Pharmaceutical CDMO Application Outlook (Revenue, USD Million, 2021-2033)
- Oncology
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Diseases
- Metabolic Disorders
- Autoimmune Diseases
- Respiratory Diseases
- Ophthalmology
- Gastrointestinal Disorders
- Hormonal Disorders
- Hematological Disorders
- Others
- Global Pharmaceutical CDMO Service Outlook (Revenue, USD Million, 2021-2033)
- Contract Development
- Contract Manufacturing
- Packaging
- Quality Control and Assurance
- Others
- Global Pharmaceutical CDMO End Use Outlook (Revenue, USD Million, 2021-2033)
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Reasons to subscribe to Global pharmaceutical cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global pharmaceutical cdmo market databook
-
Our clientele includes a mix of pharmaceutical cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global pharmaceutical cdmo market , including forecasts for subscribers. This global databook contains high-level insights into Global pharmaceutical cdmo market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Global pharmaceutical cdmo market size, by regions, 2021-2033 (US$M)
Top 10 countries: Pharmaceutical cdmo market size, 2024 (US$M)
Global pharmaceutical cdmo market share, by product, 2024 & 2033 (%, US$M)
Pharmaceutical cdmo market: Opportunity assessment by country
Global pharmaceutical cdmo market, by region, 2024 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
